Appetite Regulation

Appetite Regulation

Appetite is controlled by a tightly linked system of hormones from the body, circuits in the brain and feedback from the gut. Together they set how hungry or full you feel and how much you eat. Ghrelin, made by the stomach, stimulates appetite. Other hormones reduce it: leptin (made by fat tissue), peptide YY (PYY), cholecystokinin (CCK) and the incretin hormones GLP-1 and GIP all promote fullness and reduce food intake. These signals reach the hypothalamus, especially the arcuate nucleus. There they act on hunger-promoting neurons that make neuropeptide Y (NPY) and agouti-related peptide (AgRP), and on appetite-suppressing neurons that make pro-opiomelanocortin (POMC).

The brainstem matters too. Its nucleus of the solitary tract (NTS) gathers signals carried by the vagus nerve from the gut about how full the stomach is, what nutrients have arrived and which gut hormones have been released. Reward-driven eating, controlled by dopamine pathways in the brain’s reward system, adds another layer and can override the body’s balance signals. When these pathways go wrong, obesity can develop and persist, which makes them attractive targets for treatment.

Clinical Relevance to Retatrutide

Part of retatrutide’s weight-lowering effect comes from strong action on appetite pathways. As a GLP-1 receptor agonist, it switches on appetite-suppressing circuits in the brain and slows gastric emptying, so you feel full sooner and eat less. Its GIP and glucagon receptor activity may also affect appetite in separate but complementary ways, including effects on reward signaling and energy use. In clinical trials, people on retatrutide reported clearly less hunger and ate less food, as expected from a drug acting on several parts of the appetite system.